Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 5/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.32 |
| ▸ | MRGPRX1 | Q96LB2 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1864172 | 0.91 | TLR4 (0.57) | TLR4GRM5NAMPTMRGPRX1 | |
| SCHEMBL4157181 | 0.88 | TLR4 (0.50) | TLR4NAMPTKMT2AMRGPRX1NPC1 | |
| SCHEMBL4153029 | 0.88 | TLR4 (0.51) | TLR4NAMPTKMT2AMRGPRX1NPC1 | |
| SCHEMBL4149935 | 0.88 | TLR4 (0.51) | TLR4NAMPTKMT2AMRGPRX1NPC1 | |
| SCHEMBL4143552 | 0.86 | TLR4 (0.51) | TLR4NAMPTKMT2AMRGPRX1NPC1 | |
| SCHEMBL4146514 | 0.86 | TLR4 (0.49) | TLR4NAMPTKMT2AMRGPRX1NPC1 | |
| SCHEMBL4141115 | 0.86 | TLR4 (0.49) | TLR4NAMPTKMT2AMRGPRX1NPC1 | |
| SCHEMBL17727727 | 0.86 | TLR4 (0.49) | TLR4NAMPTKMT2AMRGPRX1NPC1 | |
| SCHEMBL14136690 | 0.86 | TLR4 (0.49) | TLR4NAMPTKMT2AMRGPRX1NPC1 | |
| SCHEMBL1864173 | 0.85 | TLR4 (0.43) | TLR4GRM5NAMPTMRGPRX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43858-E1 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1935879-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | CD40, LITAF, TNF | TLR4 29/4885GRM5 2700/4885NAMPT 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.